Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). After the treatment of standard chemotherapy R-CHOP regimen, approximately 40% of DLBCL patients fail to respond to treatment or show progress of the disease. At the 61st American Society of Hematology Annual Meeting, multiple studies reported the latest treatment progress of DLBCL, including improving the prognosis of newly diagnosed patients and providing more treatment options for relapsed/refractory DLBCL patients. Key words: Lymphoma, large B-cell, diffuse; Recurrence; Refractory; Drug therapy, combination; Molecular targeted therapy; Immunotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
